Evidence map›Paper›PMID 24182709›Full record

ArticleMayo Clinic proceedings2013

Advances in regenerative orthopedics.

Christopher H Evans

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mayo Clinic proceedings, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Equine MicroRNAs: Performance, Reproduction, and Disease.MicroRNA (Shariqah, United Arab Emirates) · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Advanced Gene Therapy Strategies for the Repair of ACL Injuries.International journal of molecular sciences · 2022
    Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 2 countries.

Christopher H EvansCenter for Advanced Orthopaedic Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Collaborative Research Center, AO Foundation, Davos, Switzerland. Electronic address: cevans@bidmc.harvard.edu.
AO Foundation · CH

Funding

Healing of Segmental Defects of Bone by Gene TransferR01AR050243 · NIAMS · MAYO CLINIC ROCHESTER · PI EVANS, CHRISTOPHER HOWARD · 2003 to 2014
$6.0M
Novel, Rapidly Translatable Technologies for Healing Long Bone Segmental DefectsRC1AR058776 · NIAMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI EVANS, CHRISTOPHER HOWARD · 2009 to 2010
$980k
NIAMS NIH HHS R01 AR050243NIAMS NIH HHS RC1 AR058776
6 · The paper itself

Abstract

Orthopedic injuries are common and a source of much misery and economic stress. Several relevant tissues, such as cartilage, meniscus, and intra-articular ligaments, do not heal. And even bone, which normally regenerates spontaneously, can fail to mend. The regeneration of orthopedic tissues requires 4 key components: cells, morphogenetic signals, scaffolds, and an appropriate mechanical environment. Although differentiated cells from the tissue in question can be used, most cellular research focuses on the use of mesenchymal stem cells. These can be retrieved from many different tissues, and one unresolved question is the degree to which the origin of the cells matters. Embryonic and induced pluripotent stem cells are also under investigation. Morphogenetic signals are most frequently supplied by individual recombinant growth factors or native mixtures provided by, for example, platelet-rich plasma; mesenchymal stem cells are also a rich source of trophic factors. Obstacles to the sustained delivery of individual growth factors can be addressed by gene transfer or smart scaffolds, but we still lack detailed, necessary information on which delivery profiles are needed. Scaffolds may be based on natural products, synthetic materials, or devitalized extracellular matrix. Strategies to combine these components to regenerate tissue can follow traditional tissue engineering practices, but these are costly, cumbersome, and not well suited to treating large numbers of individuals. More expeditious approaches make full use of intrinsic biological processes in vivo to avoid the need for ex vivo expansion of autologous cells and multiple procedures. Clinical translation remains a bottleneck.

Indexed as

Mesenchymal Stem Cell TransplantationRegenerationCell DifferentiationHumansMesenchymal Stem CellsOrthopedicsRegenerative MedicineTissue EngineeringACIautologous chondrocyte implantationBMPbone morphogenetic proteincDNAcomplementary DNADBMdemineralized bone matrixFDAFood and Drug AdministrationGAMGDFgene-activated matrixgrowth differentiation factorinduced pluripotent stemintervertebral diskiPSIVDmesenchymal stem cellMSCOAosteoarthritisPCLPDGFPLAplatelet-derived growth factorplatelet-rich plasmapolycaprolactonepolylactic acidPRPTCPTGFtransforming growth factortricalcium phosphate

Identifiers

PMID24182709
PMCPMC4214280
OpenAlexW1999730602

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.